Literature DB >> 33064984

Can Personalized Neoantigens Raise the T Cell Bar?

Neeha Zaidi1.   

Abstract

Ott et al. report the results of a phase 1B study in which a personalized neoantigen vaccine was combined with programmed death receptor-1 blockade in patients with advanced cancers. The study provides a framework for combinatorial vaccine therapies that could mount robust T cell responses, enhance tumor killing, and provide clinical benefit.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33064984      PMCID： PMC9485863          DOI： 10.1016/j.cell.2020.09.053

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   66.850


  10 in total

1.  Actively personalized vaccination trial for newly diagnosed glioblastoma.

Authors:  Norbert Hilf; Sabrina Kuttruff-Coqui; Katrin Frenzel; Valesca Bukur; Stefan Stevanović; Cécile Gouttefangeas; Michael Platten; Ghazaleh Tabatabai; Valerie Dutoit; Sjoerd H van der Burg; Per Thor Straten; Francisco Martínez-Ricarte; Berta Ponsati; Hideho Okada; Ulrik Lassen; Arie Admon; Christian H Ottensmeier; Alexander Ulges; Sebastian Kreiter; Andreas von Deimling; Marco Skardelly; Denis Migliorini; Judith R Kroep; Manja Idorn; Jordi Rodon; Jordi Piró; Hans S Poulsen; Bracha Shraibman; Katy McCann; Regina Mendrzyk; Martin Löwer; Monika Stieglbauer; Cedrik M Britten; David Capper; Marij J P Welters; Juan Sahuquillo; Katharina Kiesel; Evelyna Derhovanessian; Elisa Rusch; Lukas Bunse; Colette Song; Sandra Heesch; Claudia Wagner; Alexandra Kemmer-Brück; Jörg Ludwig; John C Castle; Oliver Schoor; Arbel D Tadmor; Edward Green; Jens Fritsche; Miriam Meyer; Nina Pawlowski; Sonja Dorner; Franziska Hoffgaard; Bernhard Rössler; Dominik Maurer; Toni Weinschenk; Carsten Reinhardt; Christoph Huber; Hans-Georg Rammensee; Harpreet Singh-Jasuja; Ugur Sahin; Pierre-Yves Dietrich; Wolfgang Wick
Journal:  Nature       Date:  2018-12-19       Impact factor: 49.962

2.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

Authors:  Derin B Keskin; Annabelle J Anandappa; Jing Sun; Itay Tirosh; Nathan D Mathewson; Shuqiang Li; Giacomo Oliveira; Anita Giobbie-Hurder; Kristen Felt; Evisa Gjini; Sachet A Shukla; Zhuting Hu; Letitia Li; Phuong M Le; Rosa L Allesøe; Alyssa R Richman; Monika S Kowalczyk; Sara Abdelrahman; Jack E Geduldig; Sarah Charbonneau; Kristine Pelton; J Bryan Iorgulescu; Liudmila Elagina; Wandi Zhang; Oriol Olive; Christine McCluskey; Lars R Olsen; Jonathan Stevens; William J Lane; Andres M Salazar; Heather Daley; Patrick Y Wen; E Antonio Chiocca; Maegan Harden; Niall J Lennon; Stacey Gabriel; Gad Getz; Eric S Lander; Aviv Regev; Jerome Ritz; Donna Neuberg; Scott J Rodig; Keith L Ligon; Mario L Suvà; Kai W Wucherpfennig; Nir Hacohen; Edward F Fritsch; Kenneth J Livak; Patrick A Ott; Catherine J Wu; David A Reardon
Journal:  Nature       Date:  2018-12-19       Impact factor: 49.962

3.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

Authors:  Vivek Verma; Rajeev K Shrimali; Shamim Ahmad; Winjie Dai; Hua Wang; Sumin Lu; Rahul Nandre; Pankaj Gaur; Jose Lopez; Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Scott A Hammond; Ming Tan; Jingjing Qi; Phillip Wong; Taha Merghoub; Jedd Wolchok; Nir Hacohen; John E Janik; Mikayel Mkrtichyan; Seema Gupta; Samir N Khleif
Journal:  Nat Immunol       Date:  2019-07-29       Impact factor: 25.606

4.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

Authors:  Mark Yarchoan; Alexander Hopkins; Elizabeth M Jaffee
Journal:  N Engl J Med       Date:  2017-12-21       Impact factor: 91.245

5.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

6.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Authors:  Ugur Sahin; Evelyna Derhovanessian; Matthias Miller; Björn-Philipp Kloke; Petra Simon; Martin Löwer; Valesca Bukur; Arbel D Tadmor; Ulrich Luxemburger; Barbara Schrörs; Tana Omokoko; Mathias Vormehr; Christian Albrecht; Anna Paruzynski; Andreas N Kuhn; Janina Buck; Sandra Heesch; Katharina H Schreeb; Felicitas Müller; Inga Ortseifer; Isabel Vogler; Eva Godehardt; Sebastian Attig; Richard Rae; Andrea Breitkreuz; Claudia Tolliver; Martin Suchan; Goran Martic; Alexander Hohberger; Patrick Sorn; Jan Diekmann; Janko Ciesla; Olga Waksmann; Alexandra-Kemmer Brück; Meike Witt; Martina Zillgen; Andree Rothermel; Barbara Kasemann; David Langer; Stefanie Bolte; Mustafa Diken; Sebastian Kreiter; Romina Nemecek; Christoffer Gebhardt; Stephan Grabbe; Christoph Höller; Jochen Utikal; Christoph Huber; Carmen Loquai; Özlem Türeci
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

7.  A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

Authors:  Patrick A Ott; Siwen Hu-Lieskovan; Bartosz Chmielowski; Ramaswamy Govindan; Aung Naing; Nina Bhardwaj; Kim Margolin; Mark M Awad; Matthew D Hellmann; Jessica J Lin; Terence Friedlander; Meghan E Bushway; Kristen N Balogh; Tracey E Sciuto; Victoria Kohler; Samantha J Turnbull; Rana Besada; Riley R Curran; Benjamin Trapp; Julian Scherer; Asaf Poran; Dewi Harjanto; Dominik Barthelme; Ying Sonia Ting; Jesse Z Dong; Yvonne Ware; Yuting Huang; Zhengping Huang; Amy Wanamaker; Lisa D Cleary; Melissa A Moles; Kelledy Manson; Joel Greshock; Zakaria S Khondker; Ed Fritsch; Michael S Rooney; Mark DeMario; Richard B Gaynor; Lakshmi Srinivasan
Journal:  Cell       Date:  2020-10-15       Impact factor: 41.582

8.  MHC-II neoantigens shape tumour immunity and response to immunotherapy.

Authors:  Elise Alspach; Danielle M Lussier; Alexander P Miceli; Ilya Kizhvatov; Michel DuPage; Adrienne M Luoma; Wei Meng; Cheryl F Lichti; Ekaterina Esaulova; Anthony N Vomund; Daniele Runci; Jeffrey P Ward; Matthew M Gubin; Ruan F V Medrano; Cora D Arthur; J Michael White; Kathleen C F Sheehan; Alex Chen; Kai W Wucherpfennig; Tyler Jacks; Emil R Unanue; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2019-10-23       Impact factor: 49.962

9.  T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Authors:  Alexander C Hopkins; Mark Yarchoan; Jennifer N Durham; Erik C Yusko; Julie A Rytlewski; Harlan S Robins; Daniel A Laheru; Dung T Le; Eric R Lutz; Elizabeth M Jaffee
Journal:  JCI Insight       Date:  2018-07-12

10.  Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development.

Authors:  Neeha Zaidi; Mariya Soban; Fangluo Chen; Heather Kinkead; Jocelyn Mathew; Mark Yarchoan; Todd D Armstrong; Shozeb Haider; Elizabeth M Jaffee
Journal:  JCI Insight       Date:  2020-09-03
  10 in total
  1 in total

Review 1.  Messenger RNA vaccines for cancer immunotherapy: progress promotes promise.

Authors:  Amanda L Huff; Elizabeth M Jaffee; Neeha Zaidi
Journal:  J Clin Invest       Date:  2022-03-15       Impact factor: 19.456
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.